[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
Identifieur interne : 000022 ( Main/Exploration ); précédent : 000021; suivant : 000023[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
Auteurs : E. Díaz [Espagne] ; R. Amézaga Menéndez [Espagne] ; P. Vidal Cortés [Espagne] ; M G Escapa [Espagne] ; B. Suberviola [Espagne] ; A. Serrano Lázaro [Espagne] ; P. Marcos Neira [Espagne] ; M. Quintana Díaz [Espagne] ; M. Catalán González [Espagne]Source :
- Medicina intensiva [ 1578-6749 ] ; 2021.
Descripteurs français
- KwdFr :
- AMP (analogues et dérivés), AMP (usage thérapeutique), Alanine (analogues et dérivés), Alanine (usage thérapeutique), Antagoniste du récepteur à l'interleukine-1 (usage thérapeutique), Anticoagulants (usage thérapeutique), Anticorps monoclonaux (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antiviraux (usage thérapeutique), Azithromycine (usage thérapeutique), Hormones corticosurrénaliennes (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Immunisation passive (MeSH), Immunoglobulines par voie veineuse (usage thérapeutique), Immunomodulation (MeSH), Inhibiteurs de protéines kinases (usage thérapeutique), Interféron bêta (usage thérapeutique), Lopinavir (usage thérapeutique), Pyrazoles (usage thérapeutique), Ritonavir (usage thérapeutique), Évolution de la maladie (MeSH).
- MESH :
- analogues et dérivés : AMP, Alanine.
- usage thérapeutique : AMP, Alanine, Antagoniste du récepteur à l'interleukine-1, Anticoagulants, Anticorps monoclonaux, Anticorps monoclonaux humanisés, Antiviraux, Azithromycine, Hormones corticosurrénaliennes, Hydroxychloroquine, Immunoglobulines par voie veineuse, Inhibiteurs de protéines kinases, Interféron bêta, Lopinavir, Pyrazoles, Ritonavir.
- Humains, Immunisation passive, Immunomodulation, Évolution de la maladie.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Adrenal Cortex Hormones (therapeutic use), Alanine (analogs & derivatives), Alanine (therapeutic use), Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Anticoagulants (therapeutic use), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), COVID-19 (drug therapy), COVID-19 (therapy), Disease Progression (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunization, Passive (MeSH), Immunoglobulins, Intravenous (therapeutic use), Immunomodulation (MeSH), Interferon-beta (therapeutic use), Interleukin 1 Receptor Antagonist Protein (therapeutic use), Lopinavir (therapeutic use), Protein Kinase Inhibitors (therapeutic use), Pyrazoles (therapeutic use), Ritonavir (therapeutic use), SARS-CoV-2 (MeSH).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , therapeutic use : Adenosine Monophosphate, Adrenal Cortex Hormones, Alanine, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Anticoagulants, Antiviral Agents, Azithromycin, Hydroxychloroquine, Immunoglobulins, Intravenous, Interferon-beta, Interleukin 1 Receptor Antagonist Protein, Lopinavir, Protein Kinase Inhibitors, Pyrazoles, Ritonavir.
- drug therapy : COVID-19.
- therapy : COVID-19.
- Disease Progression, Humans, Immunization, Passive, Immunomodulation, SARS-CoV-2.
Abstract
Infection by the SARS-CoV-2 virus, known as COVID-19 (COronaVIrus Disease-19) was initially detected in China in December 2019, and has subsequently spread rapidly throughout the world, to the point that on March 11 the World Health Organization (WHO) reported that the outbreak could be defined as a pandemic. COVID-19 disease ranges from mild flu-like episodes to other serious and even life-threatening conditions, mainly due to acute respiratory failure. These patients are frequently admitted to our Intensive Care Units in relation to acute respiratory distress syndrome. The lack of a treatment based on scientific evidence has led to the use of different management guidelines, in many cases with rapid changes in the applied protocols. Recent reviews in reputed journals have underscored the lack of proven therapies and the need for clinical trials to establish clear and objective treatment guidelines. The present study provides an update on the currently applied treatment, and intends to offer help in relation to daily care, without seeking to replace the protocols adopted in each individual center.
DOI: 10.1016/j.medin.2020.06.017
PubMed: 32854988
PubMed Central: PMC7833076
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].</title><author><name sortKey="Diaz, E" sort="Diaz, E" uniqKey="Diaz E" first="E" last="Díaz">E. Díaz</name><affiliation wicri:level="3"><nlm:affiliation>Área de Críticos, Corporación Sanitaria i Universitaria Parc Taulí, Univ. Autonoma de Barcelona, CIBER de Enfermedades Respiratorias, Sabadell, Barcelona, España. Electronic address: emilio.diaz.santos@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Área de Críticos, Corporación Sanitaria i Universitaria Parc Taulí, Univ. Autonoma de Barcelona, CIBER de Enfermedades Respiratorias, Sabadell, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Amezaga Menendez, R" sort="Amezaga Menendez, R" uniqKey="Amezaga Menendez R" first="R" last="Amézaga Menéndez">R. Amézaga Menéndez</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitari Son Espases, Palma, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitari Son Espases, Palma</wicri:regionArea><wicri:noRegion>Palma</wicri:noRegion></affiliation></author><author><name sortKey="Vidal Cortes, P" sort="Vidal Cortes, P" uniqKey="Vidal Cortes P" first="P" last="Vidal Cortés">P. Vidal Cortés</name><affiliation wicri:level="1"><nlm:affiliation>Complexo Hospitalario Universitario Ourense, Ourense, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Complexo Hospitalario Universitario Ourense, Ourense</wicri:regionArea><wicri:noRegion>Ourense</wicri:noRegion></affiliation></author><author><name sortKey="Escapa, M G" sort="Escapa, M G" uniqKey="Escapa M" first="M G" last="Escapa">M G Escapa</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario de Burgos, Burgos, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario de Burgos, Burgos</wicri:regionArea><wicri:noRegion>Burgos</wicri:noRegion></affiliation></author><author><name sortKey="Suberviola, B" sort="Suberviola, B" uniqKey="Suberviola B" first="B" last="Suberviola">B. Suberviola</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Marqués de Valdecilla, Santander, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Marqués de Valdecilla, Santander</wicri:regionArea><wicri:noRegion>Santander</wicri:noRegion></affiliation></author><author><name sortKey="Serrano Lazaro, A" sort="Serrano Lazaro, A" uniqKey="Serrano Lazaro A" first="A" last="Serrano Lázaro">A. Serrano Lázaro</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Clínico Universitario de Valencia, Valencia, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clínico Universitario de Valencia, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Marcos Neira, P" sort="Marcos Neira, P" uniqKey="Marcos Neira P" first="P" last="Marcos Neira">P. Marcos Neira</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Germans Trias y Pujol, Badalona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Germans Trias y Pujol, Badalona</wicri:regionArea><wicri:noRegion>Badalona</wicri:noRegion></affiliation></author><author><name sortKey="Quintana Diaz, M" sort="Quintana Diaz, M" uniqKey="Quintana Diaz M" first="M" last="Quintana Díaz">M. Quintana Díaz</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Universitario La Paz, Madrid, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario La Paz, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Catalan Gonzalez, M" sort="Catalan Gonzalez, M" uniqKey="Catalan Gonzalez M" first="M" last="Catalán González">M. Catalán González</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Universitario 12 de Octubre, Madrid, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:32854988</idno><idno type="pmid">32854988</idno><idno type="doi">10.1016/j.medin.2020.06.017</idno><idno type="pmc">PMC7833076</idno><idno type="wicri:Area/Main/Corpus">000D66</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000D66</idno><idno type="wicri:Area/Main/Curation">000D66</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000D66</idno><idno type="wicri:Area/Main/Exploration">000D66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].</title><author><name sortKey="Diaz, E" sort="Diaz, E" uniqKey="Diaz E" first="E" last="Díaz">E. Díaz</name><affiliation wicri:level="3"><nlm:affiliation>Área de Críticos, Corporación Sanitaria i Universitaria Parc Taulí, Univ. Autonoma de Barcelona, CIBER de Enfermedades Respiratorias, Sabadell, Barcelona, España. Electronic address: emilio.diaz.santos@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Área de Críticos, Corporación Sanitaria i Universitaria Parc Taulí, Univ. Autonoma de Barcelona, CIBER de Enfermedades Respiratorias, Sabadell, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Amezaga Menendez, R" sort="Amezaga Menendez, R" uniqKey="Amezaga Menendez R" first="R" last="Amézaga Menéndez">R. Amézaga Menéndez</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitari Son Espases, Palma, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitari Son Espases, Palma</wicri:regionArea><wicri:noRegion>Palma</wicri:noRegion></affiliation></author><author><name sortKey="Vidal Cortes, P" sort="Vidal Cortes, P" uniqKey="Vidal Cortes P" first="P" last="Vidal Cortés">P. Vidal Cortés</name><affiliation wicri:level="1"><nlm:affiliation>Complexo Hospitalario Universitario Ourense, Ourense, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Complexo Hospitalario Universitario Ourense, Ourense</wicri:regionArea><wicri:noRegion>Ourense</wicri:noRegion></affiliation></author><author><name sortKey="Escapa, M G" sort="Escapa, M G" uniqKey="Escapa M" first="M G" last="Escapa">M G Escapa</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario de Burgos, Burgos, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario de Burgos, Burgos</wicri:regionArea><wicri:noRegion>Burgos</wicri:noRegion></affiliation></author><author><name sortKey="Suberviola, B" sort="Suberviola, B" uniqKey="Suberviola B" first="B" last="Suberviola">B. Suberviola</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Marqués de Valdecilla, Santander, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Marqués de Valdecilla, Santander</wicri:regionArea><wicri:noRegion>Santander</wicri:noRegion></affiliation></author><author><name sortKey="Serrano Lazaro, A" sort="Serrano Lazaro, A" uniqKey="Serrano Lazaro A" first="A" last="Serrano Lázaro">A. Serrano Lázaro</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Clínico Universitario de Valencia, Valencia, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clínico Universitario de Valencia, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Marcos Neira, P" sort="Marcos Neira, P" uniqKey="Marcos Neira P" first="P" last="Marcos Neira">P. Marcos Neira</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Germans Trias y Pujol, Badalona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Germans Trias y Pujol, Badalona</wicri:regionArea><wicri:noRegion>Badalona</wicri:noRegion></affiliation></author><author><name sortKey="Quintana Diaz, M" sort="Quintana Diaz, M" uniqKey="Quintana Diaz M" first="M" last="Quintana Díaz">M. Quintana Díaz</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Universitario La Paz, Madrid, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario La Paz, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Catalan Gonzalez, M" sort="Catalan Gonzalez, M" uniqKey="Catalan Gonzalez M" first="M" last="Catalán González">M. Catalán González</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Universitario 12 de Octubre, Madrid, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author></analytic><series><title level="j">Medicina intensiva</title><idno type="eISSN">1578-6749</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term><term>Adenosine Monophosphate (therapeutic use)</term><term>Adrenal Cortex Hormones (therapeutic use)</term><term>Alanine (analogs & derivatives)</term><term>Alanine (therapeutic use)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Anticoagulants (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Azithromycin (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (therapy)</term><term>Disease Progression (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunization, Passive (MeSH)</term><term>Immunoglobulins, Intravenous (therapeutic use)</term><term>Immunomodulation (MeSH)</term><term>Interferon-beta (therapeutic use)</term><term>Interleukin 1 Receptor Antagonist Protein (therapeutic use)</term><term>Lopinavir (therapeutic use)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Pyrazoles (therapeutic use)</term><term>Ritonavir (therapeutic use)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term><term>AMP (usage thérapeutique)</term><term>Alanine (analogues et dérivés)</term><term>Alanine (usage thérapeutique)</term><term>Antagoniste du récepteur à l'interleukine-1 (usage thérapeutique)</term><term>Anticoagulants (usage thérapeutique)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Azithromycine (usage thérapeutique)</term><term>Hormones corticosurrénaliennes (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Immunisation passive (MeSH)</term><term>Immunoglobulines par voie veineuse (usage thérapeutique)</term><term>Immunomodulation (MeSH)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Interféron bêta (usage thérapeutique)</term><term>Lopinavir (usage thérapeutique)</term><term>Pyrazoles (usage thérapeutique)</term><term>Ritonavir (usage thérapeutique)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term><term>Adrenal Cortex Hormones</term><term>Alanine</term><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Anticoagulants</term><term>Antiviral Agents</term><term>Azithromycin</term><term>Hydroxychloroquine</term><term>Immunoglobulins, Intravenous</term><term>Interferon-beta</term><term>Interleukin 1 Receptor Antagonist Protein</term><term>Lopinavir</term><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term><term>Alanine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term><term>Alanine</term><term>Antagoniste du récepteur à l'interleukine-1</term><term>Anticoagulants</term><term>Anticorps monoclonaux</term><term>Anticorps monoclonaux humanisés</term><term>Antiviraux</term><term>Azithromycine</term><term>Hormones corticosurrénaliennes</term><term>Hydroxychloroquine</term><term>Immunoglobulines par voie veineuse</term><term>Inhibiteurs de protéines kinases</term><term>Interféron bêta</term><term>Lopinavir</term><term>Pyrazoles</term><term>Ritonavir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Humans</term><term>Immunization, Passive</term><term>Immunomodulation</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Immunisation passive</term><term>Immunomodulation</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Infection by the SARS-CoV-2 virus, known as COVID-19 (COronaVIrus Disease-19) was initially detected in China in December 2019, and has subsequently spread rapidly throughout the world, to the point that on March 11 the World Health Organization (WHO) reported that the outbreak could be defined as a pandemic. COVID-19 disease ranges from mild flu-like episodes to other serious and even life-threatening conditions, mainly due to acute respiratory failure. These patients are frequently admitted to our Intensive Care Units in relation to acute respiratory distress syndrome. The lack of a treatment based on scientific evidence has led to the use of different management guidelines, in many cases with rapid changes in the applied protocols. Recent reviews in reputed journals have underscored the lack of proven therapies and the need for clinical trials to establish clear and objective treatment guidelines. The present study provides an update on the currently applied treatment, and intends to offer help in relation to daily care, without seeking to replace the protocols adopted in each individual center.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32854988</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-6749</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>03</Month></PubDate></JournalIssue><Title>Medicina intensiva</Title><ISOAbbreviation>Med Intensiva</ISOAbbreviation></Journal><ArticleTitle>[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].</ArticleTitle><Pagination><MedlinePgn>104-121</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0210-5691(20)30247-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medin.2020.06.017</ELocationID><Abstract><AbstractText>Infection by the SARS-CoV-2 virus, known as COVID-19 (COronaVIrus Disease-19) was initially detected in China in December 2019, and has subsequently spread rapidly throughout the world, to the point that on March 11 the World Health Organization (WHO) reported that the outbreak could be defined as a pandemic. COVID-19 disease ranges from mild flu-like episodes to other serious and even life-threatening conditions, mainly due to acute respiratory failure. These patients are frequently admitted to our Intensive Care Units in relation to acute respiratory distress syndrome. The lack of a treatment based on scientific evidence has led to the use of different management guidelines, in many cases with rapid changes in the applied protocols. Recent reviews in reputed journals have underscored the lack of proven therapies and the need for clinical trials to establish clear and objective treatment guidelines. The present study provides an update on the currently applied treatment, and intends to offer help in relation to daily care, without seeking to replace the protocols adopted in each individual center.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Díaz</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Área de Críticos, Corporación Sanitaria i Universitaria Parc Taulí, Univ. Autonoma de Barcelona, CIBER de Enfermedades Respiratorias, Sabadell, Barcelona, España. Electronic address: emilio.diaz.santos@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amézaga Menéndez</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hospital Universitari Son Espases, Palma, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal Cortés</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Complexo Hospitalario Universitario Ourense, Ourense, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escapa</LastName><ForeName>M G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Hospital Universitario de Burgos, Burgos, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suberviola</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hospital Universitario Marqués de Valdecilla, Santander, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano Lázaro</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital Clínico Universitario de Valencia, Valencia, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcos Neira</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hospital Germans Trias y Pujol, Badalona, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintana Díaz</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Universitario La Paz, Madrid, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catalán González</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, España.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH).</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Intensiva</MedlineTA><NlmUniqueID>9207689</NlmUniqueID><ISSNLinking>0210-5691</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C540383">INCB018424</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>77238-31-4</RegistryNumber><NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>T4H8FMA7IM</RegistryNumber><NameOfSubstance UI="C504234">siltuximab</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="N">Immunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053590" MajorTopicYN="N">Interleukin 1 Receptor Antagonist Protein</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">ARDS-CoV-2</Keyword><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">ICU</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">Tratamiento</Keyword><Keyword MajorTopicYN="Y">Treatment</Keyword><Keyword MajorTopicYN="Y">UCI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32854988</ArticleId><ArticleId IdType="pii">S0210-5691(20)30247-3</ArticleId><ArticleId IdType="doi">10.1016/j.medin.2020.06.017</ArticleId><ArticleId IdType="pmc">PMC7833076</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li><li>Communauté de Madrid</li></region><settlement><li>Barcelone</li><li>Madrid</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Diaz, E" sort="Diaz, E" uniqKey="Diaz E" first="E" last="Díaz">E. Díaz</name></region><name sortKey="Amezaga Menendez, R" sort="Amezaga Menendez, R" uniqKey="Amezaga Menendez R" first="R" last="Amézaga Menéndez">R. Amézaga Menéndez</name><name sortKey="Catalan Gonzalez, M" sort="Catalan Gonzalez, M" uniqKey="Catalan Gonzalez M" first="M" last="Catalán González">M. Catalán González</name><name sortKey="Escapa, M G" sort="Escapa, M G" uniqKey="Escapa M" first="M G" last="Escapa">M G Escapa</name><name sortKey="Marcos Neira, P" sort="Marcos Neira, P" uniqKey="Marcos Neira P" first="P" last="Marcos Neira">P. Marcos Neira</name><name sortKey="Quintana Diaz, M" sort="Quintana Diaz, M" uniqKey="Quintana Diaz M" first="M" last="Quintana Díaz">M. Quintana Díaz</name><name sortKey="Serrano Lazaro, A" sort="Serrano Lazaro, A" uniqKey="Serrano Lazaro A" first="A" last="Serrano Lázaro">A. Serrano Lázaro</name><name sortKey="Suberviola, B" sort="Suberviola, B" uniqKey="Suberviola B" first="B" last="Suberviola">B. Suberviola</name><name sortKey="Vidal Cortes, P" sort="Vidal Cortes, P" uniqKey="Vidal Cortes P" first="P" last="Vidal Cortés">P. Vidal Cortés</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000022 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000022 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32854988
|texte= [Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32854988" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |